| 11.8 -2.03 (-14.68%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.97 |
1-year : | 17.69 |
| Resists | First : | 13.67 |
Second : | 15.14 |
| Pivot price | 12.9 |
|||
| Supports | First : | 11.3 |
Second : | 9.4 |
| MAs | MA(5) : | 13.47 |
MA(20) : | 13.01 |
| MA(100) : | 12.39 |
MA(250) : | 15.8 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 50.2 |
D(3) : | 65.3 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 55.88 | Low : | 5.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KRRO ] has closed above bottom band by 14.8%. Bollinger Bands are 16.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.37 - 14.45 | 14.45 - 14.51 |
| Low: | 11.6 - 11.68 | 11.68 - 11.75 |
| Close: | 11.68 - 11.8 | 11.8 - 11.91 |
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Tue, 15 Sep 2026
Nearly 49,000 Korro Bio (KRRO) shares sold by director-linked funds - Stock Titan
Mon, 14 Sep 2026
Korro Bio (KRRO) finance SVP’s 5-share sale comes under a preset trading plan - Stock Titan
Wed, 08 Jul 2026
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Thu, 25 Jun 2026
KRRO Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 19 Jun 2026
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Tue, 16 Jun 2026
Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.05e+007 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 1,460 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.433e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 228.3 % |
| Return on Equity (ttm) | -28 % |
| Qtrly Rev. Growth | 2.38e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -43.42 |
| EBITDA (p.s.) | -1.82311e+007 |
| Qtrly Earnings Growth | -9.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.28 |
| Price to Cash Flow | 3.78 |
| Dividend | 0 |
| Forward Dividend | 1.51e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|